Avalo Therapeutics, Inc. $AVTX Shares Purchased by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP grew its stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 34.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 770,765 shares of the company’s stock after acquiring an additional 196,882 shares during the period. Avalo Therapeutics accounts for about 2.4% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 8th biggest position. Seven Fleet Capital Management LP owned approximately 1.44% of Avalo Therapeutics worth $14,244,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of AVTX. Braidwell LP bought a new position in Avalo Therapeutics in the 2nd quarter worth approximately $30,107,000. Orbimed Advisors LLC boosted its position in Avalo Therapeutics by 39.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock valued at $17,150,000 after buying an additional 382,300 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in shares of Avalo Therapeutics by 27.6% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock valued at $20,019,000 after buying an additional 289,786 shares during the period. Nantahala Capital Management LLC increased its stake in shares of Avalo Therapeutics by 24.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock valued at $15,697,000 after buying an additional 240,000 shares during the period. Finally, Caligan Partners LP raised its position in shares of Avalo Therapeutics by 5.8% during the fourth quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock worth $16,009,000 after acquiring an additional 48,200 shares during the last quarter. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Stock Up 1.2%

Shares of Avalo Therapeutics stock opened at $19.23 on Friday. The business has a fifty day simple moving average of $19.12 and a 200 day simple moving average of $16.94. The stock has a market cap of $1.03 billion, a PE ratio of -4.40 and a beta of 0.78. Avalo Therapeutics, Inc. has a 12 month low of $9.54 and a 12 month high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.25). Analysts expect that Avalo Therapeutics, Inc. will post -2.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on AVTX shares. Wedbush cut their price target on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Mizuho boosted their price objective on Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Wall Street Zen raised shares of Avalo Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Finally, Leerink Partners began coverage on shares of Avalo Therapeutics in a research report on Monday, July 6th. They set an “outperform” rating and a $38.00 price target for the company. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $45.10.

Insider Activity at Avalo Therapeutics

In related news, insider Mittie Doyle sold 1,450 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the sale, the insider directly owned 51,776 shares in the company, valued at $931,968. This trade represents a 2.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 3,129 shares of company stock valued at $59,680. Corporate insiders own 4.46% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.